Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 615
interventional 574
Observational 37
Registry 4

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 308
Drug|Other 39
Biological|Drug 38
Biological 32
Biological|Drug|Other 28
Drug|Procedure 20
Biological|Other 11
Biological|Drug|Procedure|Radiation 8
Drug|Other|Procedure|Radiation 8
Drug|placebo 8
Biological|Drug|Other|Procedure|Radiation 6
Drug|Procedure|Radiation 6
Biological|Drug|Other|Procedure 5
Procedure 5
Biological|Drug|Procedure 4
Drug|Radiation 4
Other 4
Radiation 4
Biological|Other|Procedure 3
Drug|Genetic|Other 3
Drug|Other|Procedure 3
Biological|Drug|Radiation 2
Biological|Radiation 2
Device 2
Dietary Supplement|Other 2
Other|Procedure 2
Procedure|Radiation 2
Behavioral 1
Behavioral|Drug 1
Behavioral|Other 1
Biological|Dietary Supplement|Drug|Other|placebo 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|Radiation 1
Biological|Procedure|Radiation 1
Combination Product 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo 1
Drug|Other|placebo|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 286
China 55
France 14
NA 13
United Kingdom 11
Korea, Republic of 10
Italy 9
United States|Canada 8
Belgium|France 7
Spain 7
United States|United Kingdom 7
Germany 6
Canada 5
Japan 4
United States|Germany|Italy 4
United States|Italy 4
Australia 3
Singapore 3
Austria 2
Belgium|France|Switzerland 2
Denmark|Finland|Norway|Sweden 2
Italy|Switzerland 2
Netherlands 2
Russian Federation 2
United States|Australia 2
United States|Australia|Italy 2
United States|Denmark|Germany 2
United States|Spain 2
Algeria|Argentina|Belgium|Brazil|Bulgaria|Canada|Colombia|Finland|France|Greece|Ireland|Israel|Italy|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Serbia|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom|Venezuela 1
Argentina|Brazil|Colombia|India|Indonesia|Iran, Islamic Republic of|Malaysia|Mexico|Paraguay|Philippines|Russian Federation|South Africa 1
Australia|Austria|Belgium|France|Israel|Poland|Portugal|Spain|Switzerland 1
Australia|Austria|Bosnia and Herzegovina|Brazil|Bulgaria|China|Croatia|Czech Republic|Estonia|Hong Kong|Israel|Latvia|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|Peru|Romania|Russian Federation|Serbia|Slovakia|Slovenia|South Africa|Sweden|Taiwan|Thailand|Turkey 1
Australia|Belgium|Canada|Denmark|France|Germany|Italy|Korea, Republic of|Singapore|United Kingdom 1
Australia|United States|Belgium|Canada|China|Czechia|France|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Switzerland|Taiwan|Turkey 1
Austria|France|Norway 1
Austria|Switzerland 1
Belgium 1
Belgium|Canada|United States|Australia|France|Germany|Italy|Netherlands|Singapore|Spain|Sweden|United Kingdom 1
Belgium|Italy|Spain 1
Bosnia and Herzegovina|Croatia|Georgia|Moldova, Republic of|Poland|Serbia|Ukraine 1
Bulgaria|Estonia|France|Hungary|Italy|Latvia|Poland|Russian Federation|Spain|Ukraine 1
Czech Republic 1
Czechia|Italy|Netherlands|United Kingdom 1
Denmark|Netherlands|Spain|United Kingdom 1
Denmark|Sweden 1
France|Belgium 1
France|Germany|Russian Federation 1
France|Italy|Netherlands 1
France|Italy|Poland|Taiwan|Ukraine|Germany|United States|Australia|Canada|United Kingdom 1
Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam 1
India 1
Israel 1
Italy|Poland|United Kingdom 1
Italy|United States|Czechia|Japan|Korea, Republic of|Singapore 1
Japan|Korea, Republic of 1
Japan|United States|Argentina|Austria|Belgium|China|Czech Republic|Denmark|Estonia|Finland|Germany|Greece|Hungary|India|Ireland|Israel|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Sweden|Thailand|United Kingdom 1
Kenya|Zimbabwe 1
Malawi 1
Mexico 1
Netherlands|Belgium 1
New Zealand 1
Poland 1
Sweden 1
Switzerland|United Kingdom 1
Taiwan 1
Thailand 1
Turkey|Ukraine|Brazil|United States|Argentina|Australia|Belgium|Canada|China|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|China|Colombia|Czechia|Egypt|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|New Zealand|Norway|Peru|Poland|Russian Federation|Saudi Arabia|Singapore|Slovakia|Spain|Switzerland|Thailand|Turkey|Venezuela 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|China|Czechia|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|France|Germany|Greece|Hungary|India|Israel|Italy|Netherlands|New Zealand|Poland|Serbia|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Israel|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Croatia|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Romania|Serbia|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Italy|Japan|Netherlands|Norway 1
United States|Australia|Austria|Czechia|France|Italy|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Italy|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Australia|Belgium|Czechia|Finland|Germany|Israel|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Italy|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Spain|Turkey|United Kingdom 1
United States|Australia|Denmark|Spain 1
United States|Australia|France|Germany|Italy|Japan|Spain 1
United States|Australia|France|Germany|Netherlands|Spain 1
United States|Australia|France|Italy|Japan 1
United States|Australia|France|Poland|United Kingdom 1
United States|Australia|Israel|Italy|Korea, Republic of|Poland|Slovakia|Spain|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|Belgium|Czechia|Germany|Portugal 1
United States|Austria|Canada|Germany 1
United States|Austria|Denmark|Estonia|United Kingdom 1
United States|Belgium|Bulgaria|Czechia|Hungary|Italy|Poland|Switzerland|Ukraine 1
United States|Belgium|Canada|Germany|Korea, Republic of 1
United States|Belgium|Canada|Spain 1
United States|Belgium|Czechia|France|Germany|Hungary|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Czechia|Israel|Italy|Poland|Spain|Turkey|United Kingdom 1
United States|Belgium|France|Germany|Italy|Korea, Republic of|Spain|Turkey 1
United States|Belgium|France|Italy 1
United States|Belgium|France|Italy|Spain 1
United States|Belgium|Germany|United Kingdom 1
United States|Canada|Czechia|France|Germany|Hungary|Israel|Poland|Russian Federation|Spain|Turkey 1
United States|Canada|France|Germany|Hong Kong|Italy|Japan|Singapore|Spain 1
United States|Canada|France|Germany|Israel|Netherlands 1
United States|Canada|France|Germany|Italy 1
United States|Canada|France|Germany|Italy|Netherlands 1
United States|Canada|France|Germany|Spain|United Kingdom 1
United States|Canada|France|Italy 1
United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine 1
United States|Canada|Germany 1
United States|China 1
United States|Denmark 1
United States|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Taiwan 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|Ireland|United Kingdom 1
United States|France|Korea, Republic of 1
United States|France|Spain|United Kingdom 1
United States|Germany|Ireland|Spain|United Kingdom 1
United States|Germany|Italy|Spain|United Kingdom 1
United States|Germany|Poland 1
United States|India|Israel 1
United States|Israel|Poland|Spain 1
United States|Italy|Russian Federation|Spain 1
United States|Italy|Spain|United Kingdom 1
United States|Italy|Switzerland|United Kingdom 1
United States|Italy|United Kingdom 1
United States|Saudi Arabia 1
United States|Spain|United Kingdom 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 259
2 36
3 23
4 14
5 20
6 15
7 10
8 7
9 10
10 14
11 20
12 5
13 6
14 10
15 7
16 6
17 5
18 3
19 6
20 5
21 5
22 3
23 3
24 2
25 6
27 3
28 4
29 1
30 3
31 1
32 1
33 2
34 1
35 2
36 2
37 1
38 2
40 3
41 3
42 2
43 1
46 2
48 1
51 1
52 1
53 1
57 2
62 2
67 1
70 1
75 1
77 1
83 2
84 1
85 1
87 1
97 1
109 1
123 1
131 2
150 1
151 1
157 1
158 1
162 1
164 1
173 1
186 1
190 1
202 1
206 1
240 1
246 1
257 1
273 1
282 1
510 1
551 1

Phase

Phase Study_Count
Phase 2 220
Phase 1 164
Phase 1/Phase 2 93
Phase 3 50
N/A 30
Phase 2/Phase 3 7
Early Phase 1 6
Phase 4 4

Number of Arms

Number_of_Arms Count_of_Studies
1 360
2 118
3 35
4 18
5 6
6 5
7 3
8 3
10 2
12 1
13 1
21 1
NA 21

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 4.00000 5.0 2.00000 1.00000 5.00000 108.0000 29.00 32.0
1st Qu. 9.00000 42.5 23.50000 30.00000 36.75000 205.5000 208.50 45.5
Median 15.00000 77.0 38.00000 49.00000 60.00000 316.0000 307.00 55.0
Mean 17.33333 132.3 58.09202 78.88172 74.58636 365.5714 402.64 108.0
3rd Qu. 26.25000 159.0 69.50000 102.00000 94.00000 412.0000 571.50 117.5
Max. 33.00000 713.0 314.00000 422.00000 348.00000 900.0000 1337.00 290.0

Trial Group Type

group_type Group_Count
Experimental 836
Active Comparator 80
NA 21
Other 12
Placebo Comparator 8
No Intervention 7
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 385
Parallel Assignment 150
Sequential Assignment 29
Factorial Assignment 4
NA 4
Crossover Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 538
Supportive Care 12
Diagnostic 11
Prevention 7
Basic Science 3
Health Services Research 1
Other 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
Korea, Republic of 7
France 6
United States 5
Italy 4
NA 4
China 2
United Kingdom 2
China|Korea, Republic of|Malaysia|Singapore 1
Denmark 1
Japan 1
Serbia 1
Spain 1
United States|Canada 1
United States|France|Italy|Spain 1

Sites per Study

Site_count Study_Count
1 20
2 4
4 2
5 1
9 1
12 1
15 1
17 1
24 1
55 1
56 1
57 1
107 1
111 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 100.0000
Median 153.0000
Mean 342.2973
3rd Qu 314.0000
Max 3000.0000

Observation Model

observational_model Study_Count
Cohort 18
Case-Only 7
Other 6
Case Control 2
NA 2
Case-Control 1
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 18
Retrospective 14
Cross-Sectional 4
NA 1

Registries

Studies by Country

Country Study_Count
China 1
Denmark 1
Korea, Republic of 1
Spain 1

Sites per Study

Site_count Study_Count
1 2
14 1
24 1

Enrollment Metrics

Measure Registries
Min 75.00
1st Qu 168.75
Median 600.00
Mean 818.75
3rd Qu 1250.00
Max 2000.00

Registry Model

observational_model Study_Count
Cohort 3
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 4

Follow-up

target_duration Study_Count
2 Years 2
10 Years 1
36 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03378947 EBV-associated Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT03378947 Completed Hospices Civils de Lyon 2018-01-15
NCT03226704 Leukapheresis for CAR-Therapy Manufacturing https://ClinicalTrials.gov/show/NCT03226704 Recruiting National Institutes of Health Clinical Center (CC) 2023-05-01
NCT03211702 Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) https://ClinicalTrials.gov/show/NCT03211702 Active, not recruiting Chonbuk National University Hospital 2018-04-30
NCT03104478 Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT03104478 Recruiting The Lymphoma Academic Research Organisation 2020-12-31
NCT03042247 Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03042247 Recruiting Federico II University 2020-06-10
NCT03000192 HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life https://ClinicalTrials.gov/show/NCT03000192 Active, not recruiting University Hospital Southampton NHS Foundation Trust 2020-12-31
NCT02885623 Role of CX3CR1-expressing Cells in Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02885623 Recruiting Saint Vincent’s Hospital, Korea 2019-08-31
NCT02708732 Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02708732 Completed Hoffmann-La Roche 2016-10-31
NCT02555267 Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02555267 Active, not recruiting Chonbuk National University Hospital 2017-07-31
NCT02486952 MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02486952 Completed Hoffmann-La Roche 2011-01-31
NCT02364050 Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM https://ClinicalTrials.gov/show/NCT02364050 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2017-12-31
NCT02060435 Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT02060435 Completed Samsung Medical Center 2013-12-31
NCT01311232 Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab https://ClinicalTrials.gov/show/NCT01311232 Completed Samsung Medical Center 2012-12-01
NCT01793233 Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas https://ClinicalTrials.gov/show/NCT01793233 Active, not recruiting Children’s Oncology Group 2020-12-31
NCT01660776 BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology https://ClinicalTrials.gov/show/NCT01660776 Completed Rennes University Hospital 2017-10-02
NCT01606605 Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT01606605 Completed Samsung Medical Center 2012-12-31
NCT01563861 S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01563861 Completed Southwest Oncology Group 2008-06-01
NCT01483664 Communication Skills Intervention to Promote Transition Into Survivorship https://ClinicalTrials.gov/show/NCT01483664 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-11-30
NCT01369784 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT01369784 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2011-03-31
NCT01340443 An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01340443 Completed Hoffmann-La Roche 2016-07-15
NCT04423549 Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT04423549 Recruiting Sun Yat-sen University 2021-06-30
NCT04354402 Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL https://ClinicalTrials.gov/show/NCT04354402 Enrolling by invitation SymBio Pharmaceuticals 2020-12-31
NCT04319237 Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes https://ClinicalTrials.gov/show/NCT04319237 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-06-30
NCT04317313 Prediction of Outcome Using Pretreatment 18F-FDG PET/CT Radiomic Features in Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04317313 Completed Second Affiliated Hospital, School of Medicine, Zhejiang University 2018-09-30
NCT04183569 Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT04183569 Active, not recruiting University Hospital, Bordeaux 2020-05-01
NCT04150328 Lenalidomide Monotherapy in R/R DLBCL https://ClinicalTrials.gov/show/NCT04150328 Recruiting MorphoSys AG 2019-08-29
NCT03977623 Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression https://ClinicalTrials.gov/show/NCT03977623 Recruiting Samsung Medical Center 2022-02-28
NCT03797170 Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT03797170 Recruiting University of Bologna 2020-07-20
NCT03664336 Refractory Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT03664336 Completed Hospices Civils de Lyon 2017-07-31
NCT01266668 The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT01266668 Completed Chonbuk National University Hospital 2011-05-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01131208 Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab https://ClinicalTrials.gov/show/NCT01131208 Completed Eastern Cooperative Oncology Group 2010-08-21
NCT00949741 Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT00949741 Completed Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 2011-10-31
NCT00898157 Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494 https://ClinicalTrials.gov/show/NCT00898157 Completed Eastern Cooperative Oncology Group 2008-09-24
NCT00822432 Coproporphyrine Isomers and Methotrexate Elimination https://ClinicalTrials.gov/show/NCT00822432 Completed Assistance Publique - Hôpitaux de Paris 2011-08-31
NCT00754117 Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) https://ClinicalTrials.gov/show/NCT00754117 Completed Weill Medical College of Cornell University 2010-12-31
NCT00286832 Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV https://ClinicalTrials.gov/show/NCT00286832 Completed Copenhagen University Hospital at Herlev 2011-01-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02474550 Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT02474550 Recruiting Ajou University School of Medicine 2018-12-31
NCT04112238 ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04112238 Recruiting Herlev Hospital 2023-06-30
NCT03715296 Lenalidomide Based Immunotherapy in the Treatment of DLBCL https://ClinicalTrials.gov/show/NCT03715296 Recruiting Ruijin Hospital 2020-09-15
NCT03646422 AEDV Registry of Primary Cutaneous Lymphoma https://ClinicalTrials.gov/show/NCT03646422 Recruiting Fundación Academia Española de Dermatología 2025-01-01